A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of A Single Intravenous Dose Of GMA301 Injection In Healthy Volunteers
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Getagozumab (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Gmax Biopharm
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.
- 09 Nov 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Oct 2020 Planned End Date changed from 22 Dec 2020 to 5 Jan 2021.